This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on Web of Science (1)  • Contact me when this article is cited  Related Content  • Related letter  • Related articles  • Similar articles in JAMA  Social Bookmarking   What's this?

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

To the Editor: Dr Hlatky and colleagues¹ reported that postmenopausal hormone therapy improved quality of life only among women who reported flushing at baseline. We suspect that the women in this study who reported flushing were generally thinner than those who did not; thus, we suggest that the results should be reported stratified by body mass index (BMI). Menopausal symptoms, including flushing, are related to the dramatic decrease of estrogen levels due to depletion of ovarian function. After menopause, peripheral aromatization of androgens in adipose tissue is the primary source of endogenous estrogen, and circulating levels of estrogen in postmenopausal women increase with increasing body mass.² Significantly lower levels of estradiol and estrone are found in women with frequent hot flashes,² and flushing is more likely among thin women.²

Several observational studies have suggested that both risks and benefits of hormone therapy are observed only in thin women.^3-4 Breast cancer . . . [Full Text of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

RELATED LETTER

Quality-of-Life and Depressive Symptoms in Postmenopausal Women After Receiving Hormone Therapy: Results From the Heart and Estrogen/Progestin Replacement Study (HERS) Trial
Mark A. Hlatky, Derek Boothroyd, Eric Vittinghoff, Penny Sharp, Mary A. Whooley, and for the HERS Research Group
JAMA. 2002;287(5):591-597.
ABSTRACT | FULL TEXT  

RELATED ARTICLES

Quality-of-Life and Depressive Symptoms in Postmenopausal Women After Receiving Hormone Therapy: Results From the Heart and Estrogen/Progestin Replacement Study (HERS) Trial
Mark A. Hlatky, Derek Boothroyd, Eric Vittinghoff, Penny Sharp, Mary A. Whooley, and for the HERS Research Group
JAMA. 2002;287(5):591-597.
ABSTRACT | FULL TEXT  

Randomized Trial of Estrogen Plus Progestin for Secondary Prevention of Coronary Heart Disease in Postmenopausal Women
Stephen Hulley, Deborah Grady, Trudy Bush, Curt Furberg, David Herrington, Betty Riggs, Eric Vittinghoff, and for the Heart and Estrogen/progestin Replacement Study Research Group
JAMA. 1998;280(7):605-613.
ABSTRACT | FULL TEXT